 NEW YORK--BUSINESS WIRE--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Flexion Therapeutics, Inc. NASDAQ: FLXN to Pacira BioSciences, Inc. for 8.50 per share in cash plus one non-tradeable contingent value right worth up to 8.00 per share in cash is fair to Flexion shareholders. Halper Sadeh encourages Flexion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at 212 763-0060 